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Objective: The assessment of health-related quality-of-life (HRQoL) in rheumatoid arthritis (RA) is
becoming increasingly common in both research and clinical practice. One of the most widely used
tools for measuring HRQoL is the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36).
We conducted a systematic review examining the impact of RA on HRQoL, measured through the SF-36.
Methods: MEDLINE and Embase were searched for observational studies reporting mean and standard
deviation scores for each domain of the SF-36 in adult RA patients. Studies were reviewed in accordance
with PRISMA guidelines, and a random-effects meta-analysis was performed.
Results: In total, 31 studies were eligible for inclusion in the meta-analysis, including 22,335 patients.
Meta-analyses found that pooled mean HRQoL score for the SF-36 physical component summary was
34.1 (95% CI: 22.0–46.1) and mental component summary was 45.6 (95% CI: 30.3–60.8). Increased age
was associated with reduced physical function and physical component summary (PCS) scores but
improved mental health and mental component summary (MCS) scores. Female gender was associated
with improved scores on role physical, bodily pain and PCS but reduced mental health and MCS scores.
Longer disease duration was associated with improved MCS. Patients with RA have a substantially
reduced HRQoL in comparison to both other physical illnesses and in comparison to normative datasets
from UK and USA populations.
Conclusions: RA has a substantial impact on HRQoL. This supports recent NICE guidelines stipulating that
RA patients should be regularly assessed for the impact their disease has on HRQoL and appropriate
management provided.
& 2014 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Rheumatoid arthritis (RA) has major, diverse effects on patients'
health-related quality-of-life (HRQoL), spanning both physical and
mental domains of well-being [1]. However despite having been
measured in many studies, there are currently no systematic
reviews providing summary estimates and exploring the factors
that are most strongly associated with HRQoL. Measurement of
HRQoL is potentially useful for several reasons. Firstly, many
patients value HRQoL more than disease-related variables such
as inﬂammatory biomarkers or joint counts [2]; assessing clinical
state exclusively in terms of narrow disease activity may not
characterise the health outcomes of primary concern to patients.
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Secondly, reduced HRQoL in RA patients is associated with
increased use of healthcare resources [3] and with increased levels
of depression [4]. Therefore limiting the adverse effects of RA on
HRQoL should be a key therapeutic goal.
The Medical Outcomes Study 36-item Short-Form Health Survey
(SF-36) [5] is a popular tool for assessing HRQoL and has been used
in many physical health conditions and healthcare settings [6,7]. It
deﬁnes HRQoL as the extent to which physical health impacts an
individual's functional ability and perceived well-being in mental,
social and physical aspects of life [5]. The SF-36 has 8 individual
subscales divided across physical and psychological HRQoL domains:
Physical Function (PF), Role Physical (RP), Bodily Pain (BP), and Global
Health (GH), Vitality (V), Social Function (SF), Role Emotional (RE)
and Mental Health (MH). Scores on these subscales can be combined
to form 2 higher-order summary scores, the Physical Component
Summary (PCS) and Mental Component Summary (MCS). The PCS is
calculated by positively weighting the 4 subscales in the physical
domain (PF, RP, BP and GH) and the remaining psychological domain
subscales negatively. In contrast the MCS is calculated by positively
weighting the 4 mental domain subscales (MH, V, SF and RE), and
negatively weighting the 4 physical domain subscales.
The SF-36 has been found to be a reliable and valid measure in
RA [8], correlating well with disease-speciﬁc measures like the
Health Assessment Questionnaire (HAQ [9]) and the Arthritis
Impact Measurement Scale (AIMS [10]). However, rather than
providing a disease-speciﬁc assessment of HRQoL, as provided by
the HAQ and AIMS, the SF-36 is a generic measure, applicable to
both the normal population and other disease groups, thus
providing a useful tool for comparison of HRQoL between diseases
and in comparison to healthy populations.
Increased levels of pain, disease activity and reduced physical
function have been shown to be associated with reduced HRQoL in
RA [11,12]. The evidence from studies of other chronic diseases
suggests that a number of other factors may be expected to have an
impact, including gender, body mass index (BMI), disease severity and
age [13–15]. Several of these associated variables provide possibilities
for targeted intervention, with potential to improve both HRQoL and
physical health. To date, there has been limited systematic assessment
of the impact of RA on HRQoL, however a literature review assessing
pain and HRQoL in older patients (Z75 years) with RA found that
pain, increased age and functional limitation decreased HRQoL [16].
The present article aims to ﬁll this gap in the literature. We aim (1) to
systematically review the literature assessing the impact of RA on the
8 domains of the SF-36, (2) to provide a meta-analysed mean score
for each SF-36 domain and Physical and Mental Component Sum-
mary scores, (3) to explore the impact of study characteristics on
HRQoL scores and (4) to compare HRQoL in RA patients with HRQoL
in the general population and in other health conditions.
Patients and methods
Search strategy and selection criteria
Data extraction forms were designed in accordance with the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA [17]). MEDLINE and Embase were searched
using the Ovid platform from 1992 (when the SF-36 was devel-
oped) to October 2012. The following search terms were used:
Rheumatoid Arthritis or RA and Quality of Life or SF-36. The search
was limited to articles only published in English.
Inclusion and exclusion criteria
Our target was populations of individuals with RA whether
recruited from the general population, primary care or secondary
care samples.
Studies were included if they met the following criteria:
(1) case–control, cohort, and cross-sectional design; (2) HRQoL
assessed using the SF-36; (3) a sample size of 50 or more patients
and (4) HRQoL must have all 8 SF-36 domains recorded as mean
scores with standard deviations (SDs) or standard errors (SE).
Studies were excluded if they (1) were case-series, case-reports,
expert opinion or consensus statements; (2) included fewer than
50 patients; (3) were duplicates using the same patient data;
(4) did not record all 8 SF-36 domains with means and SDs or
(5) used a sample in which patients were selected on the basis of
their HRQoL scores (e.g., intervention trials). To maximise the
external validity of our ﬁndings, we excluded interventions and
randomised controlled trials (RCTs). RCTs tend to utilise rigorous
eligibility criteria (such as high disease activity and low levels of
comorbidity), limiting the eligibility of their results to the general
RA population [18]. Studies that reported SF-36 domain scores
normalised against the population were excluded from meta-
analysis but were assessed in a narrative synthesis.
Data extraction and quality assessment
FM conducted the primary data extraction. In order to reduce
bias, all articles were examined independently by a second
reviewer (I.S.). Inter-rater disagreement was minimal; any dis-
agreements were resolved through discussion and re-examination
of the article. When multiple publications spanned the years of
longitudinal studies, baseline levels of HRQOL were reported.
The Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) statement [19] was referred to for the develop-
ment of a purpose-built 8-point quality assessment tool (Appendix 1).
This addressed aspects of methodology that could impact reported
outcomes, and assessed the sampling method used, the sample size,
participation rate and the eligibility criteria for participation in the
studies. Articles were scored using the following scale: 0–2 ¼ low
quality, 3–5 ¼ medium quality and 6–8 ¼ high quality.
Statistical analyses
Heterogeneity was found to be high between studies, therefore
random-effects meta-analyses with 95% conﬁdence intervals (CI)
were conducted with STATA (version 10.0), using the metan
package [20]. To calculate PCS and MSC values, scores for each of
the 8 domains were extracted and standardized using a z-score
transformation. They were then multiplied by 10 and added to
50 to generate normalised scores for each domain and aggregated
using factor score coefﬁcients and creating normalised scores for
each component summary [21]. PCS and MCS scores were meta-
analysed using the standard errors provided for the Physical
Function (PF) and Mental Health (MH) domains, respectively, as
these domains represent the largest weighting within each com-
ponent summary. Heterogeneity was assessed using I2, with values
approximating 25%, 50% and 75% indicating low, moderate and
high heterogeneity, respectively [22].
Spearman's correlation analyses with adjusted r2 were used to
assess the impact of linear study variables and sample character-
istics on HRQoL scores. Additionally, the clinical variables associ-
ated with HRQoL in RA were discussed qualitatively; the wide
range of measures used and methods used to analyse data limited
meta-analytic possibilities.
Sensitivity analyses explored whether pooled mean SF-36
scores were inﬂuenced by study design. Planned sensitivity
analyses included exclusion of studies with a participation rate
Z75% or non-reported participation rate, exclusion of studies not
stating a sampling strategy or using a convenience/non-rando-
mised sampling strategy; exclusion of studies that did not state
eligibility criteria for inclusion in the study; and exclusion of
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studies using subsets of patients (e.g., a female-only sample or
patients with limited disease duration). Subgroup analyses were
planned by overall study quality, sample size, publication decade
and version of SF-36 questionnaire used, if there was more than
one study in the subgroup. A signiﬁcant difference between
primary and sensitivity and subgroup analyses was deemed
present when conﬁdence intervals did not overlap.
To make comparison with other health conditions, data from
RA patients were plotted in a graph alongside data from patients
with hypertension, congestive heart failure, type 2 diabetes,
clinical depression and myocardial infarction collected from the
SF-36 manual [23]. Normative datasets from UK [24] and the USA
[23] were used to compare HRQoL in RA patients with the HRQoL
of healthy individuals.
Results
Search results
We screened 3248 potentially relevant, non-duplicate articles
(Fig. 1). Assessment of study titles and abstracts resulted in the
exclusion of 2785 articles. The full texts of 463 articles were
assessed for eligibility, and 427 were excluded due to not meeting
eligibility criteria for inclusion. At data extraction, a further 3 were
excluded, resulting in 33 articles being deemed eligible for
inclusion. One of these articles was normalised against the general
population, and another's norm-status could not be established.
These 2 were therefore discussed in a narrative synthesis, while
the remaining 31 articles were included in the meta-analysis.
Included studies
Table 1 presents the 33 articles included in the review; full
references can be found for these studies in Appendix 2. The
studies represented a total of 22,473 patients with RA; the median
of mean ages was 53.9 years (IQR: 51.0–57.5 years), and the
median percentage of females represented in the sample was
78.3% (IQR: 73.4–81.8%). Sample sizes ranged from 50 to 13,722
participants, with a median of 156.0 (IQR: 86.0–297.0).
Quality assessment
Table 1 also shows the quality assessments for the 33 articles,
according to the quality assessment tool. The average quality of the
articles was low to moderate with a median quality score of 3.0/8.0
(IQR: 2.0–5.0). Three articles scored 0/8, and 23 (65.7%) of articles
scored 4/8 or lower. One article achieved the maximum score of 8
[25] and 2 received 7 out of 8 [26,27]. Speciﬁcally, 24.2% of studies
had a sample size larger than 300, only 39.4% stated a participation
rate and of these, only 30.8% had a participation rate over 75%, and
only 60.6% of studies reported participant eligibility criteria for
entry into the study.
Impact of RA on HRQoL
Table 2 demonstrates the pooled mean scores for the 8 SF-36
subscales, with 95% conﬁdence intervals (CI). The physical health
domains (PF, RP, BP and GH) showed lower (worse) mean scores
than the mental health domains (V, SF, RE and MH). Forest plots of
each domain meta-analysis can be found in Appendix 3. The pooled
scores for the physical health domains ranged between 36.1 and
49.0, with the lowest (worst) being RP and the highest (best) being
PF. The pooled overall PCS score was 34.1 (Fig. 2). The pooled scores
for the mental health domains ranged between 45.1 and 69.1, with
V scoring the lowest (worst) and MH showing the highest (best)
score. The pooled overall MCS score was 45.6 (Fig. 2).
Narrative synthesis of normalised studies
One study examined HRQoL in both early-stage and late-stage
Norwegian RA patients, and normalised their data against the
Norwegian population [28]. In early-stage RA, all physical domains
(PF, RP, BP and GH) were substantially lower than in the general
population. The overall mean PCS score was 37.7 (SD ¼ 5.7),
indicating a reduced overall physical HRQoL in comparison to the
Norwegian population (M ¼ 50.0, SD ¼ 10.0). Mental HRQoL (V, SF,
RE and MH) tended to not differ so greatly from population scores,
with RE and MH domains scoring slightly higher than general
population scores (51.1 and 51.2, respectively). The overall MCS score
was slightly higher than MCS in the Norwegian population (52.7,
SD ¼ 7.9). In late-stage RA, a similar pattern of scores was found.
Patients reported lower levels of PF (34.7), RP (40.8), BP (39.3) and
GH (36.8) than the general population, and overall MCS score was
substantially lower than the mean population score of 50.0 (32.5,
SD ¼ 8.0). Again, mental health scores were slightly higher, with V
and SF scoring lower than the general population (44.7 and 45.6, res-
pectively) and RE and MH scoring higher than the general population
(50.7 and 53.6, respectively). Overall MCS score was slightly higher
than MCS in the Norwegian population (55.6, SD ¼ 6.4).
One study used the ﬁrst version of the SF-36, although it could
not be conﬁrmed whether scores had been normalised against
population scores or not, as although the scores seemed low, they
had large standard deviations [29]. This study assessed HRQoL in
Italian RA patients and reported lower levels of physical HRQoL
than mental HRQoL. Patients reported low levels of PF (29.0, SD ¼
27.5), RP (15.0, SD ¼ 35.1), BP (17.7, SD ¼ 16.5) and GH (22.0, SD ¼
19.0) and low overall PCS (24.1, SD ¼ 7.1). Patient-reported mental
HRQoL was slightly higher: V (30.6, SD ¼ 23.5), SF (41.5, SD ¼
31.6), RE (30.4, SD ¼ 42.7) and MH (39.4, SD ¼ 22.7). Overall MCS
was also lower than PCS (36.1, SD ¼ 11.7). Additionally, they
looked at early RA patients and found substantially impaired
HRQoL in the physical domains and mental domains. Overall PCS
Preliminary Search
3248 papers
Excluded on Basis of Title and Abstract
2785 papers
Full-texts Assessed for Eligibility
463 papers reviewed Excluded from Review: 
427 papers
6 only qualitative data
69 experimental study designs
31 duplicated data
39 used <50 participants
155 did not use the SF-36
98 with missing SF-36 domains
23 did not record SDs or SEs
5 not primary studies
1 unusable data
36 papers eligible for data 
extraction
Excluded at data extraction:
3 papers
(4 papers recruited participants from 
the same database. The one with the 
largest sample was retained). 
31 papers included in 
meta-analysis.
2 papers included as 
narrative synthesis. 
Fig. 1. Articles identiﬁed and screened for eligibility.
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was 25.6 (SD ¼ 3.9), and overall MCS was 29.5 (SD ¼ 9.0),
suggesting that people with early RA have lower mental HRQoL
than patients with more established RA but comparable overall
physical HRQoL.
Associated study variables
Spearman's correlation analyses with adjusted r2 were used to
assess the associations between linear variables and HRQoL
Table 1
Overview of studies reporting SF-36 QoL in rheumatoid arthritis patients
References Country Study design Sampling
methoda
Qualityb Sample
size
Settingc Participation
rate (%)
Mean age
(sd)
Mean disease
duration (sd)
Women
(%)
Meta-analysis
Aggarwal, 2006 India Cross-Sectional 0 0 101 1 – 43.2 (11.7) 8.1 (5.6) 89.1
Aktekin, 2011 Turkey Cross-Sectional 1 3 166 0 – 52.5 (12.6) 10.6 (8.1) 78.3
Alishiri, 2008 Iran Cross-Sectional 1 5 411 1 9 46.8 (12.0) 6.3 (5.7) 87.3
Bartlett, 2003 USA Cross-Sectional 1 5 77 1 71.0 57.5 (13.0) – 80.5
Campolina, 2010 Brazil Cross-Sectional 0 2 200 1 – 49.2 (10.0) 11.6 (8.4) 78.0
Chermont, 2008 Brazil Cross-Sectional 1 3 100 1 – 51.0 (11.0) 11.0 (8.0) 92.0
Dadoniene, 2003 Lithuania Cross-Sectional 1 6 201 2 56.0 55.9 (10.0) 11.9 (9.5) 83.0
de Souza, 2011 Brazil Cross-Sectional 0 0 50 1 – 52.3 (7.7) 11.1 (8.0) 92.0
Eser, 2012 Turkey Cross-Sectional 0 1 150 0 – 53.3 (12.1) 12.3 (8.3) 84.0
Geuskens, 2008 The Netherlands Cross-Sectional 0 3 86 1 61.3 53.0 (14.0) 16.0 (17.0) 72.0
Ibn Yacoub, 2011 Morocco Cross-Sectional 1 3 185 1 – 46.6 (10.8) – 100.0
Ibn Yacoub, 2012 Morocco Cross-Sectional 0 2 248 1 – 47.5 (11.7) 10.6 (8.1) 79.0
Kvien, 1998 Norway Cross-Sectional 0 4 1030 2 66.4 62.3 (14.69) 12.9 (11.4) 79.0
Laas, 2009 Finland Longitudinal 0 1 97 1 – 52.0 (13.0) 17.0 75.0
Lapsley, 2002 Australia Longitudinal 0 3 81 1 70.0 58.2 (11.2) 15.6 (9.9) 80.0
Lempp, 2009 UK Cross-Sectional 0 3 125 1 – 58.9 (13.5) 12.2 (11.5) 73.8
Lie et al. [25] Norway Longitudinal 1 8 1218 3 85.0 56.4 (13.7) 4.2 (7.9) 71.3
Linde et al. [8] Denmark Cross-Sectional 0 2 200 1 – Median 59.0 Median 6.0 77.0
Linde, 2008 (b) Denmark Longitudinal 0 5 150 1 89.8 Median 60.0 – 80.0
Longford, 2011 Spain Cross-Sectional 0 3 812 1 – 60.7 (14.2) – 78.8
Mok et al. [26] China Cross-Sectional 1 7 153 1 80.6 51.7 (10.8) 6.2 (6.1) 77.0
Picavet, 2003 The Netherlands Cross-Sectional 1 5 156 2 46.9 – – –
Rupp, 2004 The Netherlands Longitudinal 0 5 679 1 56.6 59.6 (13.8) 8.7 (9.3) 71.0
Ruta, 1998 UK Cross-Sectional 1 3 240 0 – 56.0 (14.0) 13.0 (13.0) 78.3
Salafﬁ, 2002 Italy Cross-Sectional 0 1 78 1 – 56.0 7.1 70.5
Salafﬁ, 2010 Italy Cross-Sectional 1 7 469 1 62.1 57.5 (14.3) 6.1 (4.2) 71.8
Sivas, 2009 Turkey Cross-Sectional 0 0 79 0 – 42.4 (9.0) 8.6 (5.5) 100
Soderlin, 2007 Sweden Longitudinal 0 4 724 2 73.0 64.0 15.0 73.0
Thyberg, 2005 Sweden Longitudinal 0 6 297 1 92.8 55.0 (15.0) o1 year 68.0
West, 2009 Sweden Longitudinal 1 2 50 1 – 50.6 o1 year 68.0
Wolfe, 2010 USA Cross-Sectional 0 2 13,722 2 – 61.2 – 77.0
Narrative synthesis
Altinkesen and
Gelecek [28]
Turkey Cross-Sectional 0 1 78 1 – 54.5 (9.1) 10.3 (4.6) 78.2
Picchianti-
Diamanti
et al. [29]
Italy Longitudinal 1 2 60 1 – 53.0 (12.6) 5.1 (9.1) 75.0
For references see online Appendices.
a 0 ¼ convenience/non-randomised or undeﬁned sampling strategy, 1 ¼ consecutive/randomised sampling strategy.
b Quality rated out of 8: 0–2 ¼ low quality, 3–5 ¼ medium quality and 6–8 ¼ high quality.
c 0 ¼ not stated, 1 ¼ outpatient clinic, 2 ¼ database/register and 3 ¼ outpatient clinic/database.
Table 2
Meta-analysed SF-36 scores and associated study variables
SF-36 sub-group and summary scores
PF RP BP GH PCS V SF RE MH MCS
Meta-analysis results
Pooled mean 49.0 36.1 46.6 48.3 34.1 45.1 66.0 59.6 69.1 45.6
95% CI 48.7–49.4 35.8–36.5 46.3–46.9 48.0–48.6 22.0–46.1 44.8–45.4 65.7–66.4 59.0–60.1 68.8–69.3 30.3–60.8
Heterogeneity I2 (%) 94.6 97.4 98.7 98.0 0.0 97.6 98.6 96.9 99.1 0.0
Associated study variables
Study quality 0.05 0.15 0.25 0.05 0.23 0.30 0.04 0.02 0.12 0.06
Sample size 0.31 0.03 0.19 0.20 0.19 0.44* 0.23 0.07 0.10 0.13
Mean age 0.49** 0.23 0.23 0.16 0.60*** 0.36 0.15 0.20 0.47** 0.42*
Mean disease duration 0.22 0.16 0.09 0.08 0.26 0.01 0.27 0.39 0.39 0.47*
% Female 0.25 0.36* 0.53** 0.09 0.60*** 0.24 0.14 0.10 0.43* 0.42*
Publication year 0.32 0.24 0.24 0.02 0.40* 0.18 0.07 0.14 0.22 0.28
Participation rate 0.05 0.31 0.17 0.40 0.02 0.25 0.04 0.27 0.01 0.13
Note: Bold numbers denote summary scores of physical (PCS) and mental (MCS) components.
n p o 0.05.
nn p o 0.01.
nnn p o 0.001.
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(Table 2) including mean age of participants, proportion of female
participants, sample size, overall study quality, participation rate,
publication year and mean duration of illness.
Sample size was not associated with HRQoL, except for V,
which was found to be higher in smaller sample sizes (r ¼
0.44, p o 0.05). Mean age was signiﬁcantly associated with PF,
overall PCS, MH and MCS. A lower mean age was signiﬁcantly
associated with improved PF (r ¼ 0.49, p o 0.01) and higher
PCS scores (r ¼ 0.60, p o 0.001); a higher mean age was
associated improved MH (r ¼ 0.47, p o 0.01) and improved
overall MCS scores (r ¼ 0.42, p o 0.05).
Mean disease duration was associated with overall MCS score; a
longer disease duration was signiﬁcantly associated with improved
MCS scores (0.47, p o 0.05).
Signiﬁcant associations were found between the proportion of
female participants and levels of RP, BP, PCS, MH and MCS. Having
a higher proportion of female participants was signiﬁcantly
associated with improved RP (r ¼ 0.36, p o 0.05), BP (r ¼ 0.53,
p o 0.01) and overall PCS (r ¼ 0.60, p o 0.001), with poorer MH
(r ¼ 0.43, p o 0.05), and poorer overall MCS (r ¼0.42, p o
0.05). Publication year was signiﬁcantly associated with improved
PCS scores (r ¼ 0.40, p o 0.05), with more recent publication
years relating to improved PCS scores.
Sensitivity and subgroup analyses
Appendix 4 shows the pooled mean SF-36 domain scores
according to each sensitivity and subgroup analysis in comparison
to the primary analysis.
Planned sensitivity analyses included the exclusion of with
unreported participation rates (PR) or PR lower than 75%; exclud-
ing convenience, non-randomised or unreported sampling meth-
ods; excluding studies with no eligibility criteria reported;
excluding studies using subset of patients and the exclusion of
studies recruiting non-secondary care patients.
The exclusion of studies with low or unreported participation
rates signiﬁcantly reduced RP, BP, PCS, V, SF, RE and MCS scores.
Excluding studies using non-randomised, convenience or with
unspeciﬁed recruitment strategies signiﬁcantly lowered RP, BP,
GH, PCS, V, SF, RE, MH and MCS scores. Excluding studies not
reporting eligibility criteria signiﬁcantly reduced RE and MH
scores, whilst excluding studies with subsets of patients increased
RP scores. Excluding studies using SF-36 version 2 did not
signiﬁcantly alter the ﬁndings.
The subgroup analyses were performed according to overall
study quality, sample size, decade of publication and area of origin.
Reduced study quality (0–2) tended to yield higher scores on RP,
BP, GH, PCS, SF, RE, MH and MCS domains. Moderate study quality
(3–5) signiﬁcantly lowered BP scores whilst higher study quality
(6–8) reduced RP scores and increased PCS and RE scores.
Studies with smaller sample sizes (50–149) found reduced
levels of RP, PCS, RE, MH and MCS but increased V. Moderate
sample sizes (150–399) showed reduced levels of MH, whilst
studies with larger sample sizes (þ400) found reduced levels of
SF and MH. When dividing the articles up into publication decade,
studies published in the 1990s showed reduced levels of RP, GH,
PCS, V and MCS, whereas publications post-2010 indicated
improvements in RP, GH, PCS, SF, RE, MH and MCS.
Finally, data from Scandinavian patients indicated reduced RP,
PCS, V, SF, RE and MCS but improved GH in comparison to the
overall pooled scores. Studies using patients from non-
Scandinavian Europe show lower levels of PF, RP, BP, GH, PCS, SF,
MH and MCS in comparison to overall pooled scores. Asian studies
report lower levels of PF, BP, GH, SF, RE, MH and MCS but increased
RP and V. Data from American/South American studies report
higher levels of RP, BP, GH, PCS, SF, RE, MH and MCS but reduced V.
Studies from Africa show higher levels of BP, GH and PCS but lower
levels of V, SF, RE, MH and MCS.
Comparison of RA patients with other long-term conditions and
normal controls
Un-standardized data from patients with hypertension, con-
gestive heart failure, type 2 diabetes, myocardial infarction and
clinical depression were obtained from the SF-36 manual [23] and
plotted in a graph against the un-standardized RA SF-36 scores
(Fig. 3). The results of this comparison demonstrate that RA
patients show consistently lower levels of physical HRQoL compo-
nents PF, RP, BP and GH than patients with hypertension, type 2
diabetes, myocardial infarction and clinical depression. PF, RP and
GH levels are comparable in patients with RA and congestive heart
failure. Regarding mental HRQoL, RA patients score substantially
lower than patients with hypertension, type 2 diabetes and
myocardial infarction. RA and congestive heart failure patients
score similarly on levels of V, SF, RE and MH, whereas clinically
depressed patients score lower on all domains of mental HRQoL.
Figure 4 shows the pooled mean un-standardized SF-36 scores
in the RA population in comparison to scores from the UK [24] and
from the USA [23]. The ﬁgure shows that RA patients have
considerably lower HRQoL than the normal population, particu-
larly on the physical HRQoL components. A comparison between
normed SF-36 scores and normed population scores is shown in
Appendix 5.
Discussion
This systematic review aimed to examine the impact of RA on
HRQoL assessed by the SF-36, to assess the variables associated
with HRQoL, and to compare HRQoL in RA with that of the general
population and patients with other health conditions.
Our results show that RA negatively impacts HRQoL: in partic-
ular, pooled scores for the physical domains for the SF-36 are
Fig. 2. The impact of RA on SF-36 Mental and Physical Component Summaries;
meta-analysed SF-36 scores in rheumatoid arthritis patients by random-effects
meta-analysis.
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somewhat lower than the mental health domains, suggesting
that RA has a greater impact on physical HRQoL than mental
well-being. Furthermore, patients with RA have notably reduced
levels of physical function, role physical and bodily pain in
comparison to other health conditions (hypertension, congestive
heart failure, type 2 diabetes, myocardial infarction and clinical
depression). Mental HRQoL is lower in RA patients than in patients
with congestive heart failure, hypertension, myocardial infarction
and type 2 diabetes. We chose to make comparisons between
HRQoL in RA and the illnesses provided in the SF-36 manual,
which does not include a condition with a similar pain experience
to RA. Until similar reviews are conducted in conditions with
chronic pain, more reasonable between-illness comparisons are
limited.
In comparison to both the UK and the USA general population,
RA patients have lower levels of all 8 SF-36 domains. The differ-
ences between population and RA scores are particularly notable
in the physical domains: physical function, role physical, bodily
pain and global health. However RA patients also have substan-
tially lower levels of vitality, social functioning and role emotional.
These ﬁndings support previous research evidencing lower levels
of HRQoL in musculoskeletal conditions in comparison to healthy
controls [30].
Notable associations were found between age, disease duration
and proportion of female patients and SF-36 domains. A higher
mean age was associated with reduced physical functioning, and
overall PCS, which is unsurprising given that physical function
declines with age [31]. More noteworthy was the positive associ-
ation between mean age and the Mental Health domain: a higher
mean age was associated with improved levels of Mental Health.
This ﬁnding, although contradicting a previous literature review
that concluded that increased age reduced HRQoL in RA patients
aged over 75 years [16], supports the results of a recent meta-
analysis, which found a similar negative association between
depression prevalence and age in RA [32]. While there is a trend
for depression levels to increase with age in the general population
[33,34], being young may actually increase risk of poor mental
well-being in RA. A similar relationship has been reported in other
long-term conditions, including cancer [35,36], chronic obstructive
pulmonary disease (COPD) [37] and diabetes [38]. Chronic con-
ditions impact various aspects of life including employment, self-
esteem, plans for the future and developing and maintaining
Fig. 3. Comparison of QoL in RA patients to patients with hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and clinical depression, provided in
the SF-36 handbook.
Fig. 4. QoL in RA patients in comparison to the general population scores for USA and UK.
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relationships. It may be more mentally debilitating to experience
these life impacts as a younger adult than as an older patient [39].
Of additional interest is the positive association found between
disease duration and overall MCS score. Patients experiencing
symptoms for a longer duration may have a greater level of
acceptance of their condition than patients with recent onset
disease. Although this is yet to be demonstrated in an RA
population, research in other inﬂammatory conditions has found
a signiﬁcant association between disease duration and increased
disease acceptance [40]. Acceptance of illness has been found to
predict both anxiety and depressive outcomes in patients with RA
[41] and acceptance of pain has been associated with decreased
levels of depression and improved well-being [42,43]; therefore
patients with longer disease duration may have had more time to
come to terms with their condition.
It is likely that the negative association found between sample
size and vitality represents issues of study quality. Smaller sample
sizes may represent convenience sampling methods, which would
mean results may represent only patients who present themselves
for research participation, who in turn, would usually represent a
healthier patient group [44].
A ﬁnal noteworthy association was found between the propor-
tion of females and various domains of the SF-36. Studies with a
higher preponderance of females were found to have increased RP,
BP and MCS scores but lower MH and PCS scores. As the RA
patient-population represents a largely female population, this
negative association between female gender and MH may reﬂect
the increased risk of depression found in the female general
population [45]. However, it appears that being female may be
protective against poor physical HRQoL, a ﬁnding which has been
previously reported in studies with palliative care patients [46],
although it is contradictory to ﬁndings in RA patients, which
suggest that females report higher levels of pain and reduced
physical functioning [47].
Sensitivity analyses reveal that our results are sensitive to
aspects of study methodology. With the exception of excluding
studies using the SF-36 version 2, every sensitivity analysis
manipulation notably altered many results. As exclusion of the
SF-36 version 2 scores did not signiﬁcantly alter results, it appears
that the reﬁnement of the item wording and response categories
from version 1 to create version 2 supports previous research
ﬁndings that the 2 measures yield comparable results [48].
Of particular note, participation rates and sampling methods
seemed to make the most consistent impact on scores, with these
sensitivity analyses both signiﬁcantly reducing domains in both
mental and physical HRQoL. The subgroup analyses reveal differ-
ent patterns of results for different publication decades and area of
origin. Data collected post-2010 showed a signiﬁcant improvement
in many domains of both physical and mental HRQoL. This also
shows a marked improvement from studies published in both the
1990s and the 2000s. These ﬁndings would suggest that develop-
ments made in the care of RA in the past 20 years may have had a
beneﬁcial impact on HRQoL for patients. Furthermore, the country
or area in which a patient lives may impact their HRQoL; patients
in the Americas tended to show higher levels of physical and
mental well-being. However, it is important to acknowledge that
these comparisons are based on questionnaires with different
translations; mean scores may not be comparable due to different
cultural variation in both phrasings of items and responses and in
interpretation of the concept of HRQoL [49].
We decided to exclude RCTs from our analysis in order to
maximise the generalisability of our ﬁndings to the wider RA
population. A previous unsystematic assessment of baseline SF-36
domain scores in RCTs reported substantially lower scores across
all SF-36 domains in comparison to the ﬁndings from this review
[50]. This discrepancy is likely to be due to the selective
recruitment of patients into RCTs, with eligibility criteria often
selecting patients with higher disease activity and who have
previously failed ﬁrst-line treatment. This also supports our
justiﬁcation for the exclusion of such studies.
This systematic review used rigorous and reproducible meth-
ods. We used a broadly inclusive approach in our eligibility criteria,
with data representing a large number of patients worldwide.
However, as low socio-economic status (SES) patients are often
under-represented in research samples [51], the results of this
systematic review may not reﬂect lower SES patients. This can be
problematic, as low SES is associated with increased susceptibility
to RA [52] and reduced HRQoL [53]. SES was not adequately
addressed in most studies included in this review, with only single
measures of education level or monthly income commonly used to
represent patient SES. Due to this heterogeneity, the representa-
tiveness of SES of the samples was impossible to establish.
Furthermore, the majority of studies included in this review
recruited patients from hospital outpatient clinics, which may
represent the most morbid RA patients. Therefore our results may
not fully represent the RA population. Furthermore, the compar-
isons made with other physical conditions are restricted, as data
from comparator conditions are from small sample sizes and are
not pooled estimates. Therefore conclusions about the impact of
RA on HRQoL in comparison to other conditions are limited.
The SF-36 has been criticised for its conceptualization of the
higher-order summary scores as independent constructs, despite
the scoring algorithm for them involving negative weighting of all
subscale items, thus assuming dependence [21]. This limitation of
the SF-36 is thought to make interpretation of the PCS and MCS
challenging. It is recommended, however, that the component
summary scores be interpreted in conjunction with the individual
domain scores. By providing pooled SF-36 summary scores along-
side individual domain, this review can provide useful information
pertaining to this well-validated measure, which is likely to
continue to be widely used by researchers and clinicians in
rheumatological populations.
Conclusion
This article attempted to systematically quantify the impact of
RA on SF-36-measured HRQoL; the impact is substantial in both
physical and mental domains, conﬁrming HRQoL as a crucial target
for intervention [54]. Recent National Institute of Clinical Excel-
lence (NICE) guidelines stipulate that RA patients should be
periodically assessed for the impact of their disease on their lives,
including HRQoL and mood, and that access to a multidisciplinary
team is essential for the assessment and management of these
aspects of their condition [55]. The results of this systematic
review and meta-analysis support this recommendation.
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